Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review

2022 ◽  
Vol 96 ◽  
pp. 43-49
Author(s):  
Ke Xu ◽  
Hongyan Ji ◽  
Nan Hu
Author(s):  
Fardin Nabizadeh ◽  
Mohammad Balabandian ◽  
Amir Mohammad Sharafi ◽  
Ali Ghaderi ◽  
Mohammad Reza Rostami ◽  
...  

Author(s):  
Lu Xu ◽  
Bingjie He ◽  
Yunjing Zhang ◽  
Lu Chen ◽  
Dongsheng Fan ◽  
...  

2017 ◽  
Vol 88 (7) ◽  
pp. 540-549 ◽  
Author(s):  
Zhang-Yu Zou ◽  
Zhi-Rui Zhou ◽  
Chun-Hui Che ◽  
Chang-Yun Liu ◽  
Rao-Li He ◽  
...  

2018 ◽  
Vol 40 (2) ◽  
pp. 235-241 ◽  
Author(s):  
Linting Luo ◽  
Zhibin Song ◽  
Xiaoqiang Li ◽  
Huiwang ◽  
Yaqing Zeng ◽  
...  

2016 ◽  
Vol 38 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Tatiana Lins Carvalho ◽  
Lilian Maria Sanguinett de Almeida ◽  
Camila Maria Araújo Lorega ◽  
Mirella Francyne Oliveira Barata ◽  
Maria Lúcia Brito Ferreira ◽  
...  

Introduction Studies assessing symptoms of depression and anxiety in individuals with amyotrophic lateral sclerosis (ALS) have reported contradictory results. The objective of this systematic review is to identify the prevalence of these mood disorders in the literature. Methods We searched the PubMed, HighWire, MEDLINE, SciELO, LILACS and ScienceDirect databases. Literature was selected for review in two stages, according to eligibility criteria. The first stage involved searching databases and checking titles and abstracts. The second step consisted of reading complete articles and excluding those that did not meet the inclusion criteria. The inclusion criteria were articles written in Portuguese, English or Spanish, published in the last five years and involving people with ALS diagnosed according to the El Escorial criteria. Results The database searches returned a total of 1,135 titles and abstracts and then 1,117 of these were excluded. Eighteen articles were selected for review. The 12-item Amyotrophic Lateral Sclerosis Depression Inventory (ADI-12) was the only instrument designed specifically to assess depression in ALS, but it was only used in three studies. No instruments specifically designed for anxiety in ALS were used. A large number of studies found presence and slight increase of anxiety disorders. There was considerable large variation in the results related to depressive disorders, ranging from moderate depression to an absence of symptoms. Conclusions Patients with ALS may exhibit symptoms of depression and anxiety at different levels, but there is a need for studies using specific instruments with larger samples in order to ascertain the prevalence of symptoms in ALS and the factors associated with it.


2016 ◽  
Vol 3 (2) ◽  
pp. e00023
Author(s):  
J. M. Gregory ◽  
F. M. Waldron ◽  
T. Soane ◽  
L. Fulton ◽  
D. Leighton ◽  
...  

2020 ◽  
Vol 10 (3) ◽  
pp. 58 ◽  
Author(s):  
Owen Connolly ◽  
Laura Le Gall ◽  
Gavin McCluskey ◽  
Colette G Donaghy ◽  
William J Duddy ◽  
...  

Amyotrophic lateral sclerosis is a rare and fatal neurodegenerative disease characterised by progressive deterioration of upper and lower motor neurons that eventually culminates in severe muscle atrophy, respiratory failure and death. There is a concerning lack of understanding regarding the mechanisms that lead to the onset of ALS and as a result there are no reliable biomarkers that aid in the early detection of the disease nor is there an effective treatment. This review first considers the clinical phenotypes associated with ALS, and discusses the broad categorisation of ALS and ALS-mimic diseases into upper and lower motor neuron diseases, before focusing on the genetic aetiology of ALS and considering the potential relationship of mutations of different genes to variations in phenotype. For this purpose, a systematic review is conducted collating data from 107 original published clinical studies on monogenic forms of the disease, surveying the age and site of onset, disease duration and motor neuron involvement. The collected data highlight the complexity of the disease’s genotype–phenotype relationship, and thus the need for a nuanced approach to the development of clinical assays and therapeutics.


Sign in / Sign up

Export Citation Format

Share Document